Nurix Therapeutics (NRIX) EBT Margin (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed EBT Margin for 7 consecutive years, with 576.13% as the latest value for Q4 2025.
- On a quarterly basis, EBT Margin fell 13544.0% to 576.13% in Q4 2025 year-over-year; TTM through Nov 2025 was 301.6%, a 5276.0% increase, with the full-year FY2025 number at 314.0%, up 4036.0% from a year prior.
- EBT Margin was 576.13% for Q4 2025 at Nurix Therapeutics, up from 761.62% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 79.14% in Q2 2023 to a low of 761.62% in Q3 2025.
- A 5-year average of 383.0% and a median of 379.17% in 2024 define the central range for EBT Margin.
- Peak YoY movement for EBT Margin: surged 41196bps in 2023, then tumbled -37336bps in 2025.
- Nurix Therapeutics' EBT Margin stood at 509.17% in 2021, then plummeted by -35bps to 688.74% in 2022, then surged by 60bps to 276.77% in 2023, then plummeted by -59bps to 440.69% in 2024, then tumbled by -31bps to 576.13% in 2025.
- Per Business Quant, the three most recent readings for NRIX's EBT Margin are 576.13% (Q4 2025), 761.62% (Q3 2025), and 96.93% (Q2 2025).